STOCK TITAN

Verastem, Inc. - VSTM STOCK NEWS

Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.

Verastem, Inc. (NASDAQ: VSTM) is a pioneering biopharmaceutical company dedicated to discovering and developing innovative drugs that target cancer stem cells. These cells are a significant factor in tumor recurrence and metastasis, posing a substantial challenge in the treatment of various cancers. Verastem's mission is to translate groundbreaking cancer stem cell research into new medicines that address major cancers, including breast cancer.

The core focus of Verastem lies in advancing novel anticancer agents, particularly those inhibiting critical signaling pathways that promote cancer cell survival and tumor growth. This includes the development of RAF/MEK inhibitors and FAK inhibitors. These targeted therapies are designed to intercept the mechanisms that allow cancer cells to thrive and spread, offering hope for more effective treatments.

One of the company's notable projects involves the combination of avutometinib (a RAF/MEK clamp) and defactinib (a FAK inhibitor). This drug combination has shown promising results and has been granted breakthrough therapy designation for treating recurrent low-grade serous ovarian cancer (LGSOC), regardless of KRAS status, after one or more prior lines of therapy, including platinum-based chemotherapy.

Verastem has also entered into a strategic partnership with GenFleet Therapeutics, a clinical-stage biotechnology company. This collaboration aims to advance three oncology programs, with GFH375 being the first selected candidate. GFH375, an oral KRAS G12D inhibitor, targets both the

Rhea-AI Summary
Verastem Oncology (VSTM) grants stock options to new employees as an inducement material to their employment. The options allow the purchase of 35,000 shares at $11.73 per share, vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
none
-
Rhea-AI Summary
SGO 2024 findings reveal significant concerns among respondents regarding life expectancy, treatment side effects, and emotional well-being.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
-
Rhea-AI Summary
Verastem Oncology (VSTM) reports progress in developing combination therapies for cancer, including Phase 3 trials and FDA Fast Track designation. Financial results for Q4 2023 and full year released.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
Rhea-AI Summary
Verastem Oncology (Nasdaq: VSTM) presented multiple oral and poster presentations at the SGO 2024 Annual Meeting on Women’s Cancer. The presentations included a late-breaking oral presentation of avutometinib and defactinib combination data from the RAMP 201 Part A trial in heavily pretreated patients with low-grade serous ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
-
Rhea-AI Summary
Verastem Oncology receives FDA Orphan Drug Designation for avutometinib and defactinib in recurrent low-grade serous ovarian cancer, aiming for Accelerated Approval in 2024. The company is addressing a rare cancer with no approved treatments, impacting a significant patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
-
Rhea-AI Summary
Verastem Oncology announces promising preclinical data on GFH375 (VS-7375) and avutometinib-FAK inhibitor combination for pancreatic and colorectal cancer treatment. Partner GenFleet to submit IND in H1 2024. Key presentations at AACR Annual Meeting 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
none
Rhea-AI Summary
Verastem Oncology (VSTM) plans to submit an NDA for Accelerated Approval for the combination of avutometinib and defactinib in recurrent low-grade serous ovarian cancer in the first half of 2024. They also aim to provide data read-outs with avutometinib and defactinib combinations in KRAS G12C-mutant non-small cell lung cancer and frontline metastatic pancreatic cancer, as well as supporting their collaborator GenFleet in advancing oral KRAS G12D inhibitor GFH375/VS-7375 into a Phase 1 clinical trial this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.12%
Tags
none
-
Rhea-AI Summary
Verastem Oncology (VSTM) announced that the FDA has granted Fast Track Designation to its investigational RAF/MEK clamp, avutometinib, in combination with Amgen’s KRAS G12C inhibitor, LUMAKRASTM (sotorasib), for the treatment of patients with KRAS G12C-mutant metastatic non-small cell lung cancer (NSCLC). Initial RAMP 203 trial results showed confirmed responses in both KRAS G12C inhibitor resistant and naïve patients. Enrollment is ongoing in the expansion phase, with updated results expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
-
Rhea-AI Summary
Verastem Oncology (VSTM) to participate in fireside chat at B. Riley Securities 4th Annual Oncology Conference on January 18, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
conferences
Rhea-AI Summary
Verastem Oncology (VSTM) Grants Stock Options to New Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
none

FAQ

What does Verastem, Inc. specialize in?

Verastem, Inc. specializes in developing novel drugs that target cancer stem cells to treat various major cancers, including breast cancer.

What are some of Verastem's key projects?

Verastem is working on RAF/MEK and FAK inhibitors to treat cancer. They are also developing a combination therapy of avutometinib and defactinib for low-grade serous ovarian cancer.

Who are Verastem's partners?

One of Verastem's key partners is GenFleet Therapeutics, with whom they are collaborating to advance oncology programs targeting KRAS mutations.

What is GFH375?

GFH375 is an oral KRAS G12D inhibitor being developed in collaboration with GenFleet Therapeutics. It targets cancer cells with KRAS G12D mutations.

What makes Verastem's approach unique?

Verastem focuses on cancer stem cells, aiming to develop therapies that prevent tumor recurrence and metastasis, a major challenge in cancer treatment.

What are RAF/MEK and FAK inhibitors?

RAF/MEK and FAK inhibitors are drugs that target specific signaling pathways in cancer cells, hindering their growth and survival.

What types of cancer is Verastem targeting?

Verastem is targeting major cancers, including breast cancer, ovarian cancer, and those with KRAS mutations.

What recent achievements has Verastem made?

Verastem's combination therapy of avutometinib and defactinib has been granted breakthrough therapy designation for treating recurrent low-grade serous ovarian cancer.

How does Verastem's partnership with GenFleet Therapeutics benefit their research?

The partnership allows Verastem to leverage GenFleet's expertise in oncology to advance new therapies targeting KRAS mutations, enhancing their oncology pipeline.

Where can I find more information about Verastem, Inc.?

More information can be found on their official website: www.verastem.com.

Verastem, Inc.

Nasdaq:VSTM

VSTM Rankings

VSTM Stock Data

85.09M
25.33M
0.6%
66.89%
5.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEEDHAM